Aron Jaffe, Ph.D.
“I am excited to work at the convergence of biology and technology in order to create therapies with transformational impact.”
At Third Rock, Aron focuses on drug discovery and development opportunities across our portfolio. He brings more than 20 years of target and drug discovery experience in academia and industry settings, and lectures frequently at international research conferences. Prior to joining Third Rock, Aron spent 11 years at the Novartis Institutes for BioMedical Research, where he established the ‘3D biology’ group in the Developmental and Molecular Pathways Department, led the Regenerative Medicine and Microbiome groups in the Chemical Biology and Therapeutics Department, and ultimately co-led the Respiratory Disease program. Aron and his groups collaborated broadly across both Novartis and the academic community to advance new technologies, address fundamental questions in cell biology, and identify novel therapeutic targets to restore tissue function.
Aron’s passion lies in building organizations from the ground up across broad therapeutic areas of unmet need. He is enthusiastic about the future of the biotech industry, and sees the most potential in purposeful exploration at the convergence of biology and technology in order to create therapies with transformational impact. Aron has co-authored numerous publications in high-impact journals such as Cell and Nature, including the recent discovery the pulmonary ionocyte, a new cell type in the mammalian lung. Outside the office, Aron enjoys spending time with his family, and is very proud of his baseball-obsessed son.